|Mr. Eddie Gray||Chief Exec. Officer and Director||602k||N/A||58|
|Dr. Dennis A. Carson Ph.D., M.D.||Co-Founder and Director||40k||N/A||70|
|Mr. Michael S. Ostrach J.D.||Chief Financial Officer, Chief Bus. Officer and Sr. VP||427k||N/A||65|
|Mr. David F. Novack||Sr. VP of Operations and Quality||388.25k||N/A||55|
|Dr. Robert L. Coffman Ph.D.||Chief Scientific Officer and Sr. VP||468.8k||N/A||70|
Dynavax Technologies Corporation, a clinical-stage immunotherapy company, focuses on leveraging the power of the bodys innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. The companys lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, an investigational cancer immunotherapeutic that is in Phase I/II studies. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for the treatment of for multiple malignancies, as well as DV281 for the treatment of non-small cell lung cancer. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for varios immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.
Dynavax Technologies Corporation’s ISS Governance QualityScore as of June 2, 2017 is 9. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 10; Compensation: 9.